We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

3 Apr 2008 07:00

Akers Biosciences, Inc.03 April 2008 Embargoed: 0700hrs, 3 April 2008 Akers Biosciences, Inc. ("ABI" or the "Company") ABI Names Thomas A. Nicolette CEO ABI, the developer, manufacturer and supplier of rapid diagnostic testingequipment, announces the appointment of a new Chief Executive Officer and otherchanges to its Board. Having successfully begun the execution of the Company's transition of emphasisfrom R&D into volume sales of its core products over the past twelve months,Thomas A. Nicolette has become CEO of ABI with immediate effect. Dr Raymond F.Akers Jr., following a period of 12 years as Chief Executive Officer duringwhich he has bought forward, from concept through to completion, the 6 platformtechnologies that form the basis of the ABI's commercial offering today, willnow hold the position of Executive Vice Chairman of the Board. He will continueto lead the development of new products and technical support of ABI's existingproduct portfolio. Robert J. Paratore, who has served as a senior member of the finance departmentof ABI for 6 years, latterly as its Financial Controller, has been promoted toChief Financial Officer. Thomas A. Nicolette, President & CEO, commented, "These changes to the structure of the Board reflect the progress over the pastyear in which we have successfully identified and delivered sustainable routesto market of our products, up-scaled our marketing efforts worldwide andappointed one of the UK's leading investment banks for growth companies. Webelieve we now have the right team positioned to drive ABI forward to deliverinvestors the most value from over a decade of product development." The Company will publish its financial results for 2007 on Monday 7 April 2008. Enquiries: Thomas A. Nicolette President and CEO Tel. +1 856 848 8698 Ben Simons or Eleanor Williamson M:Communications Tel. +44 (0)20 7153 1540 Alasdair Younie Arbuthnot Securities Limited Tel. +44 (0)20 7012 2139 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Mar 20197:00 amRNSResult of Special Meeting of Shareholders
6th Feb 20199:00 amRNSHolding in Company
6th Feb 20197:01 amRNSForm DEFA14A Filing - Additional Proxy Materials
6th Feb 20197:00 amRNSNotice of Special Meeting of Shareholders
5th Feb 20191:00 pmRNSFurther Re. Directorate Change
28th Jan 20197:00 amRNSForm PRE 14A Filing
28th Dec 20183:45 pmRNSDirector/PDMR Shareholding
19th Dec 20184:45 pmRNSIntention to Delist from AIM
18th Dec 20186:00 pmRNSIssue of Equity
10th Dec 20187:00 amRNSResult of AGM & Form 8-K Filing
26th Nov 20182:00 pmRNSFurther Re. Notice of AGM
19th Nov 20182:00 pmRNSFurther Re. Strategic Update
16th Nov 20184:00 pmRNSReverse Stock Split Update
15th Nov 20187:00 amRNSNotice of AGM
15th Nov 20187:00 amRNS3rd Quarter 2018 Results
12th Nov 20187:00 amRNSForm 8-K Filing
8th Nov 20187:30 amRNSSuspension - Akers Biosciences, Inc.
8th Nov 20187:00 amRNSTemporary Suspension of Share Trading on LSE
7th Nov 20182:50 pmRNSStrategic Update & Reverse Stock Split
2nd Nov 20184:15 pmRNSIssue of Equity - Completion & Form 8-K/A Filing
2nd Nov 201810:52 amRNSUpdate Re Issue of Equity
31st Oct 20181:35 pmRNSIssue of Equity & Form 8-K
19th Oct 20182:53 pmRNSForm 8-K Filing
19th Oct 20187:00 amRNSDirectorate Change
12th Oct 20187:00 amRNSForm 8-K/A Filing & Other Updates
8th Oct 20187:00 amRNSDirectorate Change & Other Information
13th Sep 20187:00 amRNSDirectorate Change - Form 8-K Filing
15th Aug 20187:00 amRNS2nd Quarter & H1 2018 Results
27th Jul 20183:00 pmRNSHolding(s) in Company
26th Jul 20187:30 amRNSRestoration - Akers Biosciences Inc.
26th Jul 20187:00 amRNSMailing of 2017 Annual Report
20th Jul 20183:05 pmRNSIssue of Equity
20th Jul 20183:00 pmRNSCorrection: Issue of Equity
18th Jul 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
16th Jul 20187:03 amRNS1st Quarter 2018 Results
16th Jul 20187:02 amRNSFinal Results 2017 (Restated)
16th Jul 20187:01 amRNS3rd Quarter 2017 Results (Restated)
16th Jul 20187:00 amRNS2nd Quarter 2017 Results (Restated)
3rd Jul 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
2nd Jul 20187:30 amRNSSuspension - Akers Bioscience, Inc
29th Jun 20187:00 amRNSTemporary Suspension
21st Jun 20187:00 amRNSNotification of Class Action
20th Jun 20187:22 amRNSForm 8-K Filing
18th Jun 20187:00 amRNSForm 8-K Filing
6th Jun 20187:00 amRNSForm 8-K/A Filing
4th Jun 20187:00 amRNSForm 8-K Filing
31st May 20187:25 amRNSUpdate Re. Nasdaq Minimum Bid Price Requirement
29th May 20187:00 amRNSDirectorate Change
29th May 20187:00 amRNSWithdrawal of 510(k) Submission - Chlamydia Assay
29th May 20187:00 amRNSNotice of Form 10-Q Filing Delinquency from Nasdaq

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.